These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1291 related items for PubMed ID: 29971628

  • 1. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Kabil N, Bayraktar R, Kahraman N, Mokhlis HA, Calin GA, Lopez-Berestein G, Ozpolat B.
    Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
    [Abstract] [Full Text] [Related]

  • 2. Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.
    Bircan HA, Gurbuz N, Pataer A, Caner A, Kahraman N, Bayraktar E, Bayraktar R, Erdogan MA, Kabil N, Ozpolat B.
    Lung Cancer; 2018 Oct; 124():31-39. PubMed ID: 30268477
    [Abstract] [Full Text] [Related]

  • 3. Thymoquinone Inhibits Proliferation and Migration of MDA-MB-231 Triple Negative Breast Cancer Cells by Suppressing Autophagy, Beclin-1 and LC3.
    Ünal TD, Hamurcu Z, Delibaşı N, Çınar V, Güler A, Gökçe S, Nurdinov N, Ozpolat B.
    Anticancer Agents Med Chem; 2021 Oct; 21(3):355-364. PubMed ID: 32767958
    [Abstract] [Full Text] [Related]

  • 4. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z, Ashour A, Kahraman N, Ozpolat B.
    Oncotarget; 2016 Mar 29; 7(13):16619-35. PubMed ID: 26918606
    [Abstract] [Full Text] [Related]

  • 5. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.
    Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, Ozpolat B.
    PLoS One; 2012 Mar 29; 7(7):e41171. PubMed ID: 22911754
    [Abstract] [Full Text] [Related]

  • 6. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
    Bayraktar R, Pichler M, Kanlikilicer P, Ivan C, Bayraktar E, Kahraman N, Aslan B, Oguztuzun S, Ulasli M, Arslan A, Calin G, Lopez-Berestein G, Ozpolat B.
    Oncotarget; 2017 Feb 14; 8(7):11641-11658. PubMed ID: 28036267
    [Abstract] [Full Text] [Related]

  • 7. Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer.
    Shahbazi R, Asik E, Kahraman N, Turk M, Ozpolat B, Ulubayram K.
    Nanomedicine (Lond); 2017 Aug 14; 12(16):1961-1973. PubMed ID: 28745127
    [Abstract] [Full Text] [Related]

  • 8. Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion.
    Ashour AA, Gurbuz N, Alpay SN, Abdel-Aziz AA, Mansour AM, Huo L, Ozpolat B.
    J Cell Mol Med; 2014 Nov 14; 18(11):2235-51. PubMed ID: 25215932
    [Abstract] [Full Text] [Related]

  • 9. Tryptophan hydroxylase 1 and 5-HT7 receptor preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling.
    Gautam J, Banskota S, Regmi SC, Ahn S, Jeon YH, Jeong H, Kim SJ, Nam TG, Jeong BS, Kim JA.
    Mol Cancer; 2016 Nov 21; 15(1):75. PubMed ID: 27871326
    [Abstract] [Full Text] [Related]

  • 10. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
    Bayraktar R, Ivan C, Bayraktar E, Kanlikilicer P, Kabil NN, Kahraman N, Mokhlis HA, Karakas D, Rodriguez-Aguayo C, Arslan A, Sheng J, Wong S, Lopez-Berestein G, Calin GA, Ozpolat B.
    Clin Cancer Res; 2018 Sep 01; 24(17):4225-4241. PubMed ID: 29748184
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
    Martin JL, Julovi SM, Lin MZ, de Silva HC, Boyle FM, Baxter RC.
    Breast Cancer Res; 2017 Aug 04; 19(1):90. PubMed ID: 28778177
    [Abstract] [Full Text] [Related]

  • 12. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC, Wang JX, Han ML, Zhang LP, Li L.
    Cell Oncol (Dordr); 2017 Apr 04; 40(2):157-166. PubMed ID: 28054302
    [Abstract] [Full Text] [Related]

  • 13. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
    Choi SK, Kim HS, Jin T, Hwang EH, Jung M, Moon WK.
    BMC Cancer; 2016 Aug 02; 16():570. PubMed ID: 27484639
    [Abstract] [Full Text] [Related]

  • 14. Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells.
    Adinew GM, Messeha SS, Taka E, Badisa RB, Antonie LM, Soliman KFA.
    Nutrients; 2022 May 19; 14(10):. PubMed ID: 35631261
    [Abstract] [Full Text] [Related]

  • 15. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S, Lee J, Jeon M, Lee JE, Nam SJ.
    Oncotarget; 2016 Jan 12; 7(2):1544-58. PubMed ID: 26637807
    [Abstract] [Full Text] [Related]

  • 16. Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy.
    Guan Y, Jiang S, Ye W, Ren X, Wang X, Zhang Y, Yin M, Wang K, Tao Y, Yang J, Cao D, Cheng Y.
    Cell Death Dis; 2020 Nov 03; 11(11):948. PubMed ID: 33144562
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
    Shen Y, Zhang W, Liu J, He J, Cao R, Chen X, Peng X, Xu H, Zhao Q, Zhong J, Ding W, Lei X, Jiang Y, Zu X.
    Int J Cancer; 2019 Feb 01; 144(3):651-664. PubMed ID: 30289981
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S, Liu Y, Guevara ML, Blanco E, Choi DS, Qian W, Patel T, Rodriguez AA, Cusimano J, Weiss HL, Zhao H, Landis MD, Dave B, Gross SS, Chang JC.
    Breast Cancer Res; 2015 Feb 22; 17(1):25. PubMed ID: 25849745
    [Abstract] [Full Text] [Related]

  • 19. TQFL12, a novel synthetic derivative of TQ, inhibits triple-negative breast cancer metastasis and invasion through activating AMPK/ACC pathway.
    Wei C, Zou H, Xiao T, Liu X, Wang Q, Cheng J, Fu S, Peng J, Xie X, Fu J.
    J Cell Mol Med; 2021 Nov 22; 25(21):10101-10110. PubMed ID: 34609056
    [Abstract] [Full Text] [Related]

  • 20. The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer.
    Şakalar Ç, İzgi K, İskender B, Sezen S, Aksu H, Çakır M, Kurt B, Turan A, Canatan H.
    Tumour Biol; 2016 Apr 22; 37(4):4467-77. PubMed ID: 26500095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.